Currently, pembrolizumab and nivolumab, which target PD-1 receptors, have been approved for the first- and second-line treatment of NSCLC, respectively.[5,14,15] Other PD-1/PD-L1 inhibitors are in various stages of clinical development. Here, CD274 is linked to non-small cell lung carcinoma.